• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Arthritis Rheumatol . Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes by disease-related blood biomarkers

tetano

Editor, Senior Moderator
Arthritis Rheumatol


. 2021 Apr 20.
doi: 10.1002/art.41763. Online ahead of print.
Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes by disease-related blood biomarkers


Christoph Kessel[SUP] 1 [/SUP], Richard Vollenberg[SUP] 2 [/SUP], Katja Masjosthusmann[SUP] 3 [/SUP], Claas Hinze[SUP] 1 [/SUP], Helmut Wittkowski[SUP] 1 [/SUP], France Debaugnies[SUP] 4 5 [/SUP], Carole Nagant[SUP] 6 [/SUP], Francis Corazza[SUP] 4 6 [/SUP], Fr?d?ric V?ly[SUP] 7 8 [/SUP], Gilles Kaplanski[SUP] 9 10 11 [/SUP], Charlotte Girard-Guyonvarc'h[SUP] 11 [/SUP], Cem Gabay[SUP] 11 [/SUP], Hartmut Schmidt[SUP] 2 [/SUP], Dirk Foell[SUP] 1 [/SUP], Phil-Robin Tepasse[SUP] 2 [/SUP]



Affiliations

Abstract

Objectives: Infection with the novel coronavirus SARS-CoV-2 triggers severe illness with high mortality in a subgroup of patients. Such critical course of coronavirus disease (COVID)-19 is thought to associate with cytokine storm as in macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (sHLH), although these specific data are still lacking. In this study we aimed to directly address the question, whether immune activation in COVID-19 does indeed mimic conditions as in these classical cytokine storm syndromes.
Methods: We quantified levels of 22 biomarkers in serum samples of COVID-19 (n=30, n=83 longitudinal samples in total), sHLH/MAS patients (n=50) as well as healthy controls (n=9) using bead array assay as well as single-marker ELISA and correlated results with disease outcome.
Results: In sHLH/MAS we observed dramatic activation of the interleukin(IL)-18-interferon (IFN)-? axis, while increased serum levels of IL-1 receptor antagonist (IL-1Ra), intracellular adhesion molecule 1 (ICAM-1) and IL-8, as well as strongly reduced levels of soluble Fas ligand (sFasL) in course of SARS-CoV-2 infection discriminate immune dysregulation in critical COVID-19 from the investigated well-recognized cytokine storm conditions.
Conclusions: Serum biomarker profiles clearly separate COVID-19 from MAS or sHLH, which questions the significance of systemic hyperinflammation following SARS-CoV-2 infection as well as the efficacy of drugs targeting key molecules and pathways specifically associated with systemic cytokine storm conditions in the treatment of COVID-19.

Keywords: COVID-19; biomarkers; cytokine storm; macrophage activation syndrome.
 
Back
Top Bottom